Sana Biotechnology

The $800M cell engineering company pioneering fusosome delivery technology to insert therapeutic genes directly into target cells in the body. Sana is attacking blood cancers, genetic disorders, and autoimmune disease with its unique platform, which is 40% faster than the average cell therapy rival in preclinical development time.